Cyclophilin inhibitors.
The percentage of patients chronically infected with hepatitis C virus (HCV) who have reached sustained antiviral response has increased since the introduction of the pegylated interferon-alpha (pIFNa) and ribavirin (RBV) treatment. However, the current standard pIFNa/RBV therapy not only has a low success rate (about 50%) but is often associated with serious side effects. Thus, there is an urgent need for the development of new anti-HCV agents. Cyclophilin (Cyp) inhibitors are among the most promising of the new anti-HCV agents under development. Recent clinical studies demonstrate that Cyp inhibitors are potent anti-HCV drugs, with a novel mechanism of action and efficacy profiles that make them attractive candidates for combination with current and future HCV treatments.
Gallay
Philippe A
PA
Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA. gallay@scripps.edu
D000998:Antiviral Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D021983:Cyclophilins / Q000037:antagonists & inhibitors*; D016572:Cyclosporine / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D003524:Cyclosporins / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D055808:Drug Discovery; D016174:Hepacivirus / Q000187:drug effects; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D014779:Virus Replication / Q000187:drug effects
D000998:Antiviral Agents; D003524:Cyclosporins; D016572:Cyclosporine; C090438:(melle-4)cyclosporin; D021983:Cyclophilins; C499715:alisporivir; C544142:SCY-635